TABLE 1.
| MICT (n=30) | HIIT (n=90) | p-value | |
|---|---|---|---|
| Age, mean ± SD, y | 67±16 | 67±12 | P=.84 |
| Female sex, n (%) | 8 (27) | 24 (27) | P>.99 |
| BMI, mean ± SD, kg/m2 | 30.3±4.5 | 29.5±4.8 | P=.42 |
| Height, mean ± SD, cm | 169±2 | 172±1 | P=.08 |
| Body weight, mean ± SD, kg | 86.6±3.0 | 87.5±1.7 | P=.80 |
| Days between CR and MI, mean ± SD, days | 14±6 | 14±10 | P=.15 |
| Co-morbidities, n (%) | |||
| PCI | 14 (47) | 39 (43) | P=.75 |
| CABG | 9 (30) | 17 (19) | P=.20 |
| Hyperglycemia | 3 (10) | 10 (11) | P>.99 |
| Hypertension | 24 (80) | 78 (87) | P=.38 |
| Dyslipidemia | 12 (40) | 41 (46) | P=.60 |
| Metabolic syndrome | 10 (33) | 33 (36.7) | P=.74 |
| Ever Smoker | 12 (40) | 38 (42) | P=.83 |
| Medications, n (%) | |||
| ACEIs/ARBs | 15 (50) | 49 (54) | P=.67 |
| Antiplatelet drugs | 24 (80) | 88 (98) | P=.003 |
| Anticoagulants | 1 (3) | 3 (3) | P>.99 |
| Beta receptor blockers | 23 (77) | 74 (82) | P=.50 |
| CCBs | 4 (13) | 18 (20) | P=.59 |
| Diuretics | 7 (23) | 6 (7) | P=.02 |
| Digoxin | 3 (10) | 0 | P=.01 |
| Nitrates | 5 (17) | 12 (13) | P=.65 |
| Statins | 27 (90) | 85 (94) | P=.41 |
| VO2peak, ml·kg−1·min−1 | 23.03±7.33 | 22.82±5.85 | P=.90 |
a
ACEIs = indicates angiotensin-converting enzyme inhibitors; ARBs = angiotensin II receptor blockers; BMI = body mass index; CABG = coronary artery bypass grafting; CCBs = Calcium channel blockers; HIIT = high-intensity interval training; MICT = moderate-intensity continuous training, PCI = percutaneous coronary intervention; VO2peak = maximal oxygen consumed.
b
Data are reported as Mean ± Standard deviation or number and percent population (%). Values were analyzed with two-sample t-test or Wilcoxon rank-sum test for continuous variables and Chi-square or Fisher exact test for categorical variables.